Tirzepatide

AdipoGen Life Sciences
Product Code: AG-CP3-0043
Product Group: Other Biochemicals
CodeSizePrice
AG-CP3-0043-M0055 mg£100.00
Quantity:
AG-CP3-0043-M02525 mg£320.00
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
AMBIENT
Storage:
Short term storage:+4°C. Long term storage:-20°C.

Images

1 / 1
Chemical Structure

Chemical Structure

Further Information

Alternate Names/Synonyms:
LY3298176; Mounjaro
Appearance:
White lyophilized powder.
CAS:
2023788-19-2
EClass:
32160000
Form (Short):
solid
Handling Advice:
Keep cool and dry.
InChi:
InChI=1S/C225H348N48O68/c1-23-126(10)183(264-198(311)146(64-50-52-88-226)246-202(315)157(109-180(297)298)252-199(312)152(103-124(6)7)261-223(337)225(21,22)269-217(330)185(128(12)25-3)266-209(322)163(120-278)257-200(313)153(107-138-74-78-141(282)79-75-138)250-203(316)158(110-181(299)300)253-207(320)162(119-277)259-216(329)187(134(18)280)267-206(319)155(106-136-60-44-41-45-61-136)254-215(328)186(133(17)279)262-174(289)114-237-193(306)147(83-87-179(295)296)260-222(336)224(19,20)268-192(305)143(227)104-137-72-76-140(281)77-73-137)214(327)242-131(15)190(303)244-148(80-84-168(228)283)196(309)245-145(65-51-53-89-231-175(290)121-340-100-99-339-97-91-233-176(291)122-341-101-98-338-96-90-232-170(285)86-82-150(221(334)335)243-171(286)70-46-38-36-34-32-30-28-26-27-29-31-33-35-37-39-47-71-178(293)294)195(308)240-130(14)191(304)248-154(105-135-58-42-40-43-59-135)205(318)263-182(125(8)9)212(325)247-149(81-85-169(229)284)197(310)251-156(108-139-111-234-144-63-49-48-62-142(139)144)201(314)249-151(102-123(4)5)204(317)265-184(127(11)24-2)213(326)241-129(13)189(302)236-112-172(287)235-115-177(292)270-92-54-66-164(270)210(323)258-161(118-276)208(321)256-160(117-275)194(307)238-113-173(288)239-132(16)218(331)272-94-56-68-166(272)220(333)273-95-57-69-167(273)219(332)271-93-55-67-165(271)211(324)255-159(116-274)188(230)301/h40-45,48-49,58-63,72-79,111,123-134,143,145-167,182-187,234,274-282H,23-39,46-47,50-57,64-71,80-110,112-122,226-227H2,1-22H3,(H2,228,283)(H2,229,284)(H2,230,301)(H,231,290)(H,232,285)(H,233,291)(H,235,287)(H,236,302)(H,237,306)(H,238,307)(H,239,288)(H,240,308)(H,241,326)(H,242,327)(H,243,286)(H,244,303)(H,245,309)(H,246,315)(H,247,325)(H,248,304)(H,249,314)(H,250,316)(H,251,310)(H,252,312)(H,253,320)(H,254,328)(H,255,324)(H,256,321)(H,257,313)(H,258,323)(H,259,329)(H,260,336)(H,261,337)(H,262,289)(H,263,318)(H,264,311)(H,265,317)(H,266,322)(H,267,319)(H,268,305)(H,269,330)(H,293,294)(H,295,296)(H,297,298)(H,299,300)(H,334,335)/t126-,127-,128-,129-,130-,131-,132-,133+,134+,143-,145-,146-,147-,148-,149-,150+,151-,152-,153-,154-,155-,156-,157-,158-,159-,160-,161-,162-,163-,164-,165-,166-,167-,182-,183-,184-,185-,186-,187-/m0/s1
InChiKey:
BTSOGEDATSQOAF-SMAAHMJQSA-N
Long Description:
Chemical. CAS: 2023788-19-2. Formula: C225H348N48O68. MW: 4813.5. Tirzepatide is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. Tirzepatide potently activates the GLP-1R signaling pathway to stimulate glucose-dependent insulin secretion through activity at the GIP receptor (GIPR) or the GLP-1R. Tirzepatide is a synthetic peptide with glucose-lowering effects. It is an antidiabetic agent against type 2 diabetes (T2D), stimulating insulin and suppressing glucagon secretion in a glucose-dependent manner. Tirzepatide was also shown to delay gastric emptying, lower fasting and postprandial glucose concentration, decrease food intake and reduce body weight in patients with type 2 diabetes. Tirzepatide comprises a 39 amino acid linear synthetic peptide conjugated to a C20 fatty diacid moiety through a hydrophilic linker at the lysine residue at position 20. Due to this moiety, the compound is highly bound to albumin in the plasma which prolongs its half-life. It contains two non-coded amino acid residues (Aib, alpha-amino isobutyric acid) at positions 2 and 13).
Molecular Formula:
C225H348N48O68
Molecular Weight:
4813.5
Package Type:
Vial
Product Description:
Tirzepatide is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. Tirzepatide potently activates the GLP-1R signaling pathway to stimulate glucose-dependent insulin secretion through activity at the GIP receptor (GIPR) or the GLP-1R. Tirzepatide is a synthetic peptide with glucose-lowering effects. It is an antidiabetic agent against type 2 diabetes (T2D), stimulating insulin and suppressing glucagon secretion in a glucose-dependent manner. Tirzepatide was also shown to delay gastric emptying, lower fasting and postprandial glucose concentration, decrease food intake and reduce body weight in patients with type 2 diabetes. Tirzepatide comprises a 39 amino acid linear synthetic peptide conjugated to a C20 fatty diacid moiety through a hydrophilic linker at the lysine residue at position 20. Due to this moiety, the compound is highly bound to albumin in the plasma which prolongs its half-life. It contains two non-coded amino acid residues (Aib, alpha-amino isobutyric acid) at positions 2 and 13).
Purity:
>98% (HPLC)
Sequence:
H-Tyr-{Aib}-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-{Aib}-Leu-Asp-Lys-Ile-Ala-Gln-{diacid-gamma-Glu-(AEEA)2-Lys}-Ala-Phe-Val-Gln-Trp-Leu-Ile-Ala-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2
SMILES:
N[C@H](C(NC(C)(C)C(N[C@@H](CCC(O)=O)C(NCC(N[C@]([C@H](O)C)([H])C(N[C@H](C(N[C@]([C@H](O)C)([H])C(N[C@@H](CO)C(N[C@H](C(N[C@H](C(N[C@@H](CO)C(N[C@]([C@@H](C)CC)([H])C(NC(C)(C)C(N[C@@H](CC(C)C)C(N[C@H](C(N[C@@H](CCCCN)C(N[C@]([C@@H](C)CC)([H])C(N[C@H](C(N[C@@H](CCC(N)=O)C(N[C@@H](CCCCNC(COCCOCCNC(COCCOCCNC(CC[C@H](C(O)=O)NC(CCCCCCCCCCCCCCCCCCC(O)=O)=O)=O)=O)=O)C(N[C@H](C(N[C@H](C(N[C@@H](C(C)C)C(N[C@@H](CCC(N)=O)C(N[C@H](C(N[C@@H](CC(C)C)C(N[C@]([C@@H](C)CC)([H])C(N[C@H](C(NCC(NCC(N1CCC[C@H]1C(N[C@@H](CO)C(N[C@@H](CO)C(NCC(N[C@H](C(N2CCC[C@H]2C(N3CCC[C@H]3C(N4CCC[C@H]4C(N[C@@H](CO)C(N)=O)=O)=O)=O)=O)C)=O)=O)=O)=O)=O)=O)=O)C)=O)=O)=O)CC5=CNC6=C5C=CC=C6)=O)=O)=O)CC7=CC=CC=C7)=O)C)=O)=O)=O)C)=O)=O)=O)CC(O)=O)=O)=O)=O)=O)=O)CC(C=C8)=CC=C8O)=O)CC(O)=O)=O)=O)=O)CC9=CC=CC=C9)=O)=O)=O)=O)=O)CC%10=CC=C(O)C=C%10
Solubility Chemicals:
Soluble in aqueous solution (5% AcOH) (1mg/ml).
Source / Host:
Synthetic.
Transportation:
Non-hazardous
UNSPSC Number:
12352200
Use & Stability:
Stable for at least 1 year after receipt when stored at -20°C.

References

LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept: T. Coskun, et al.; Mol. Metab. 18, 3 (2018) | Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial: J.P. Frias, et al.; Lancet 392, 2180 (2018) | Pharmacological characterization of mono-, dual- and tri-peptidic agonists at GIP and GLP-1 receptors: E. Yuliantie, et al.; Biochem. Pharmacol. 177, 114001 (2020) | The novel dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long-acting GLP-1 receptor agonists: S. Urva, et al.; Diabetes Obes. Metab. 22, 1886 (2020) | Tirzepatide: a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) dual agonist in development for the treatment of type 2 diabetes: J.P. Frias; Expert Rev. Endocrinol. Metab. 15, 379 (2020) (Review) | Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes: M.K. Thomas, et al.; J. Clin. Endocrinol. Metab. 106, 388 (2021) | Tirzepatide, a New Era of Dual-Targeted Treatment for Diabetes and Obesity: A Mini-Review: V.P. Chavda, et al.; Molecules 27, 4315 (2022) (Review)